← All trials
NCT05306704
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 15, 2019
- Primary completion
- Jan 31, 2022
- Completion date
- Jan 31, 2022
- First posted
- Apr 1, 2022
- Last posted
- Apr 11, 2022
- Enrollment
- 95
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of the PunjabLead sponsor
- Services Hospital, LahoreReponsible party - principal investigator
- Services Hospital, LahoreSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.